Cyclodextrins and Oligonucleotide Delivery to Solid Tumours

Abstract

Cyclodextrins (CyDs) have traditionally been used for dissolving hydrophobic chemicals into aqueous media, and more recently, for inducing cholesterol efflux from lipid-laden cells as a proposed mechanism for reversal of cardiovascular disease. This review discusses the potential of delivering therapeutic oligonucleotides to solid tumours using CyD molecules. The physicochemical properties of these oligosaccharide molecules, and the barriers posed by the solid tumour itself, factors that affect may affect the uptake of oligonucleotides by CyDs, are the major foci of this review.

RECK—a newly discovered inhibitor of metastasis with prognostic significance in multiple forms of cancer

“…With viral vectors though, there is the potential for further neoplastic change to occur when transfecting an already unstable genome [34]. Thus, use of non-viral vectors such as liposomes [35], microplexes [36,37], cyclodextrins [38] and nanoparticles [39], may be more appropriate for gene transfer. What is needed now are studies outlining whether RECK is needed for normal development, apart from what is now known regarding its role in angiogenesis and vasculogenesis.…”

Cancer, chitosan nanoparticles and catalytic nucleic acids

“…Nonviral vectors range from liposomes to nanoparticles made up of various materials including ceramics, polymers and metals. Although nonviral vectors are generally more advantageous in terms of safety, ease of preparation, flexibility for vector to be tailor‐made and cost‐ effective, their use is not without complications 35–37 . As nonviral vectors can be synthesised using a variety of materials ranging from biomaterials to even gold, multiple dose administrations of nucleic acid‐complexed vectors may heighten immunostimulation.…”

Non-viral methods for gene transfer towards osteosarcoma therapy

“…These include nanoparticles (Dass 2004a), dendrimers (Fahmy et al 2003), and cyclodextrins (Dass 2004b), all of which have been have been shown to transfect tumours in vivo. Furthermore, slowrelease carriers such as microspheres , microplexes (Dass and Burton 2003) or implants (Walker et al 2002;Dass and Choong 2006c), which deliver the genotherapeutic construct at a sustained rate, may prove worthwhile.…”